ADHD Medications: Adderall vs Vyvanse, How Stimulants Work and Complete 2026 Treatment Guide
ADHD medications account for 22% of all prescription drug searches in the United States — making them collectively the single most searched medication category in the country. Approximately 10% of US children and 4–5% of adults carry a diagnosis of attention-deficit/hyperactivity disorder (ADHD), representing over 40 million Americans — a significant proportion of whom are prescribed stimulant medications to manage the condition. Adderall (amphetamine salts) and Vyvanse (lisdexamfetamine) are the two most commonly searched and prescribed stimulants in this category.
Yet despite the enormous scale of ADHD medication use, the fundamental questions patients and families have are frequently inadequately answered: What is the actual difference between Adderall and Vyvanse? Why can Vyvanse not simply be converted to Adderall on a milligram-for-milligram basis? Why do stimulants work for ADHD when they seem like they would make the condition worse? What should patients do during the ongoing shortage that has persisted since 2022? And when should non-stimulant alternatives be considered?
This complete 2026 guide answers all of these questions — covering the neuroscience of ADHD, how stimulant medications work at the molecular level, the difference between immediate-release and extended-release formulations, an accurate Adderall vs Vyvanse comparison including correct dosage equivalency, methylphenidate as an alternative stimulant class, the non-stimulant options for patients who cannot tolerate stimulants, side effects and who should not use stimulants, and what the 2026 medication shortage landscape looks like for patients.
The CDC provides guidance on ADHD treatment and medication options at: https://www.cdc.gov/adhd/treatment/index.html
What is ADHD? — The Neuroscience
Attention-deficit/hyperactivity disorder is a neurodevelopmental condition characterised by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning across multiple settings. It is not a character flaw or a failure of willpower — it is a neurological difference in brain development and function that affects executive function, working memory, emotional regulation, and the ability to sustain attention.
The brain chemistry of ADHD:
The core neurochemical deficiency in ADHD involves reduced dopamine and norepinephrine signalling in the prefrontal cortex — the brain region responsible for executive functions including planning, organisation, working memory, impulse control, and sustained attention.
Dopamine: the brain's motivation and reward neurotransmitter; in ADHD, dopamine signalling in the prefrontal cortex is reduced, impairing the ability to engage with tasks that are not immediately rewarding or novel
Norepinephrine: regulates arousal, attention, and response inhibition; reduced noradrenergic signalling contributes to distractibility, hyperactivity, and impulsivity
Why stimulants help rather than worsen ADHD:
This is the most counterintuitive aspect of ADHD pharmacology. Stimulant medications increase dopamine and norepinephrine in the prefrontal cortex — improving the signal-to-noise ratio of executive function networks. The result is that the brain's regulatory systems can function more effectively, reducing the inattention, hyperactivity, and impulsivity that characterise the condition. The "stimulant paradox" in ADHD reflects that these individuals have an underactivated prefrontal cortex, and stimulant medication brings this to a more functional activation level rather than over-stimulating it.
Types of ADHD:
ADHD predominantly inattentive presentation (previously "ADD"): difficulty sustaining attention, easily distracted, forgetful, disorganised; often overlooked in children and adults because hyperactivity is not prominent
ADHD predominantly hyperactive-impulsive presentation: fidgeting, inability to stay seated, excessive talking, acting without thinking; more visible and more commonly diagnosed in childhood
ADHD combined presentation: both inattention and hyperactivity-impulsivity; the most common presentation overall
ADHD in adults — the underdiagnosed majority:
ADHD was historically considered a childhood condition. We now know that approximately 60–80% of children with ADHD continue to have significant symptoms into adulthood, and that many adults receive their first diagnosis in their 30s, 40s, or beyond. Adult ADHD often presents differently from childhood ADHD: less visible hyperactivity and more prominent inattention, executive dysfunction, emotional dysregulation, chronic lateness, relationship difficulties, and career underachievement.
Stimulant Medications — Two Classes
All FDA-approved stimulant ADHD medications belong to one of two classes:
Class 1 — Amphetamines:
Amphetamines work by directly stimulating the release of dopamine and norepinephrine from nerve terminals AND blocking their reuptake transporters. This dual mechanism produces a larger, more potent catecholamine effect than reuptake inhibition alone:
Adderall (amphetamine salts — mixed salts of amphetamine): contains 75% dextroamphetamine and 25% levoamphetamine — the specific ratio produces a combination of rapid onset (levo-component) and sustained effect (dextro-component)
Vyvanse (lisdexamfetamine dimesylate): a prodrug — lisdexamfetamine is pharmacologically inactive until converted by enzymes in red blood cells to the active dextroamphetamine; this conversion is gradual and produces smoother, longer-duration effects
Dexedrine (dextroamphetamine): pure dextroamphetamine; generally stronger per milligram than mixed salts Adderall
Class 2 — Methylphenidate:
Methylphenidate works by blocking the reuptake of dopamine and norepinephrine without significantly increasing release — a more targeted mechanism producing somewhat milder effects than amphetamines in most patients:
Ritalin (methylphenidate IR): immediate-release; 3–5 hour duration
Concerta (methylphenidate ER): extended-release; OROS delivery system; 8–12 hours
Focalin (dexmethylphenidate): the more active d-isomer of methylphenidate; approximately twice as potent per milligram as regular methylphenidate
Adderall vs Vyvanse — The Critical Differences
Feature | Adderall IR | Adderall XR | Vyvanse (Lisdexamfetamine) |
Active ingredient | Mixed amphetamine salts | Mixed amphetamine salts | Lisdexamfetamine → dextroamphetamine (prodrug) |
Formulation type | Immediate release | Extended release (50% IR + 50% delayed) | Extended release — prodrug conversion |
Onset of action | 30–45 minutes | 30–45 minutes | 1–2 hours (slower — prodrug conversion) |
Peak effect | 1–3 hours | 3–4 hours | 3–4 hours |
Duration of effect | 4–6 hours | 6–8 hours | 10–14 hours |
Abuse potential | Higher — faster onset | Moderate | Lower — prodrug delays onset; cannot be crushed to speed up |
FDA-approved ages | 3 years and older | 6 years and older | 6 years and older (ADHD); 18+ (binge-eating disorder) |
Additional indications | Narcolepsy | Narcolepsy | Binge-eating disorder |
Generic available? | Yes | Yes | Yes — since August 2023 (14 manufacturers approved) |
Switching from Vyvanse to Adderall | NOT mg-for-mg — Vyvanse requires higher mg for equivalent effect | — | — |
The dose conversion issue — why switching is not straightforward:
One of the most searched questions about ADHD medications is how to convert between Vyvanse and Adderall. The answer: they are not equivalent on a milligram-per-milligram basis. Vyvanse 30mg is approximately equivalent to Adderall XR 10mg; Vyvanse 70mg is approximately equivalent to Adderall XR 20–25mg. Switching from a higher Vyvanse dose to an equivalent Adderall dose requires prescribing a significantly lower milligram amount of Adderall — and individual response varies. Always work with a prescribing physician when switching between ADHD medications.
Dosage Guide — Starting Doses and Titration
ADHD medications are always started at the lowest effective dose and titrated upward gradually based on response and tolerability. The goal is the minimum effective dose — not the maximum.
Adderall IR dosing:
Children 6–12: start 5mg once or twice daily; increase by 5mg weekly; maximum 40mg/day
Adolescents and adults: start 5–10mg once or twice daily; increase by 5–10mg weekly; maximum 60mg/day (though doses above 40mg rarely provide additional benefit)
Adderall XR dosing:
Children 6–12: start 5–10mg once daily in the morning; increase by 5–10mg weekly; maximum 30mg/day
Adolescents: start 10mg once daily; maximum 40mg/day
Adults: start 20mg once daily; adjust based on response
Vyvanse dosing:
Children 6–12 and adults: start 20–30mg once daily in the morning; increase by 10–20mg weekly; maximum 70mg/day
Always taken in the morning — the 10–14 hour duration means afternoon or evening dosing causes significant insomnia
Methylphenidate (Concerta ER) dosing:
Children and adolescents: start 18mg once daily; increase by 18mg weekly; maximum 54mg/day (under 13) or 72mg/day (13+)
Adults: start 18–36mg once daily; maximum 72mg/day
Key dosing principles:
Take stimulants in the morning — afternoon dosing causes insomnia
Take with or without food — food does not significantly affect efficacy but taking with food reduces appetite suppression effects at mealtime
"Medication holidays" on weekends or school breaks: sometimes used for children where social/home functioning is less impaired than school functioning; not appropriate for all patients — discuss with prescriber; adults generally need consistent dosing
If appetite suppression is severe: take with a substantial breakfast before the medication is absorbed; ensure adequate caloric intake at dinner when medication has worn off
Side Effects — Complete Profile
Common side effects (stimulant class effects):
Decreased appetite and weight loss — the most common; particularly prominent at lunchtime when medication peaks; monitor growth in children
Insomnia — especially if taken too late in the day; typically improves with correct morning-only timing
Increased heart rate and blood pressure — mild; clinically significant in patients with pre-existing cardiovascular disease
Headache — particularly early in treatment; typically improves
Dry mouth
Irritability and emotional lability — particularly as medication wears off (the "rebound" effect); more prominent with shorter-acting formulations
Less common but important:
Growth suppression in children — long-term stimulant use associated with modest reduction in growth velocity; monitor height and weight; generally recovers during medication holidays or after discontinuation
Tics — stimulants can worsen existing tic disorders; use with caution in Tourette syndrome
Mood changes — anxiety, agitation, or exacerbation of underlying mood disorders
Psychosis — rare at therapeutic doses; risk increases with high doses; contraindicated in patients with psychotic disorders
Cardiovascular safety:
ADHD stimulants cause modest increases in heart rate (approximately 3–4 bpm average) and blood pressure (approximately 2–4 mmHg). The FDA has required a black box warning noting the potential for serious cardiovascular events in patients with pre-existing structural cardiac abnormalities. Routine electrocardiogram is not required before starting stimulants in otherwise healthy individuals but is recommended if there is a family or personal history of serious cardiac abnormalities, sudden death, or arrhythmia.
Absolute contraindications for stimulants:
Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs) — risk of hypertensive crisis; potentially fatal
Known serious structural cardiac abnormalities, cardiomyopathy, or serious cardiac arrhythmias
Hypersensitivity to amphetamine (for amphetamine-based stimulants) or methylphenidate
Symptomatic cardiovascular disease
Moderate to severe hypertension
Non-Stimulant ADHD Medications — When Stimulants Are Not Appropriate
For patients who cannot tolerate stimulants, have contraindications, or prefer non-stimulant options, evidence-based alternatives exist:
Atomoxetine (Strattera):
The first non-stimulant FDA-approved for ADHD (2002). A selective norepinephrine reuptake inhibitor (SNRI) that increases norepinephrine in the prefrontal cortex. Unlike stimulants, it is not a controlled substance — no abuse potential. Takes 2–6 weeks to reach full effect (unlike the immediate effect of stimulants). Effective for both inattentive and hyperactive symptoms. Can cause initial nausea and somnolence; also carries a black box warning for suicidal ideation in children and adolescents (same as antidepressant class). Good option for patients with comorbid anxiety.
Viloxazine (Qelbree):
A newer non-stimulant approved in 2021 for children and adolescents, and in 2023 for adults. A norepinephrine reuptake inhibitor with additional serotonergic activity. Once-daily capsule. May have slightly faster onset than atomoxetine. Not a controlled substance.
Guanfacine (Intuniv) and clonidine (Kapvay):
Alpha-2A adrenergic receptor agonists originally developed for hypertension. Approved for ADHD, particularly effective for hyperactivity, impulsivity, and emotional dysregulation. Often used as adjuncts to stimulants or as alternatives for patients who cannot tolerate stimulants. Guanfacine may reduce anxiety — useful in patients with comorbid anxiety and ADHD. Side effects: sedation, low blood pressure, bradycardia.
For our guide on anxiety disorders — ADHD and anxiety disorders are highly comorbid (approximately 50% of adults with ADHD have comorbid anxiety); non-stimulant ADHD treatment often preferred when anxiety is severe: [Anxiety Disorders: Types, Symptoms, Causes and Treatment]
For our guide on bupropion — used off-label for adult ADHD with comorbid depression; the only antidepressant with meaningful evidence for ADHD as well as depression: [Bupropion (Wellbutrin/Zyban): Uses, How It Works and Complete 2026 Guide]
For our guide on sleep — ADHD is strongly associated with sleep disorders; addressing sleep is a critical component of comprehensive ADHD management: [Sleep Deprivation: How Fatigue Affects Health]
A comprehensive NIH PMC review of stimulant medications for ADHD — mechanisms, efficacy, and safety — is available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441936/
MedlinePlus provides comprehensive patient information on amphetamine medications at: https://medlineplus.gov/druginfo/meds/a605027.html
The 2026 ADHD Medication Shortage — What Patients Need to Know
The Adderall shortage — declared by the FDA in October 2022 — has continued into 2026 with some improvement but persistent regional and formulation-specific shortages. Key 2026 updates:
Generic Vyvanse (lisdexamfetamine): FDA approved 14 manufacturers to produce generic lisdexamfetamine in 2023; supply has improved significantly but some shortages persist in specific strengths and regions
Generic Adderall: brand-name Adderall shortage has largely resolved; generic amphetamine salt combos still experience periodic regional shortages
What to do during a shortage:
Contact multiple pharmacies — shortage availability varies by location and pharmacy chain
Ask your prescriber about therapeutic alternatives: switching between formulations (IR to XR), switching between stimulant classes (amphetamine to methylphenidate), or temporarily trialling a non-stimulant
Do not abruptly stop ADHD medication without medical guidance — sudden discontinuation does not cause physical withdrawal symptoms (stimulants do not cause physical dependence in the way opioids or benzodiazepines do) but symptoms of ADHD return immediately
Frequently Asked Questions
What is the difference between Adderall and Vyvanse for ADHD?
Both contain amphetamine as their active component but work differently. Adderall contains mixed amphetamine salts (75% dextroamphetamine, 25% levoamphetamine) and acts within 30 to 45 minutes, lasting 4 to 6 hours (IR) or 6 to 8 hours (XR). Vyvanse contains lisdexamfetamine — an inactive prodrug that must be converted by enzymes in red blood cells to active dextroamphetamine. This conversion makes Vyvanse slower to onset (1 to 2 hours), but also smoother, longer-lasting (10 to 14 hours), and with lower abuse potential because it cannot be crushed or snorted to speed up the effect. They cannot be switched milligram-for-milligram — Vyvanse 30mg is approximately equivalent to Adderall XR 10mg.
Why do stimulants help ADHD when they seem like they would make it worse?
This is the most counterintuitive aspect of ADHD treatment. Stimulant medications increase dopamine and norepinephrine signalling specifically in the prefrontal cortex — the brain region responsible for executive function, attention, and impulse control. In people with ADHD, this region is underactivated due to reduced neurotransmitter signalling. Stimulants bring prefrontal function closer to an optimal level — improving the brain's ability to regulate attention and behaviour rather than over-stimulating it. The result is increased calm focus rather than the stimulation non-ADHD individuals would experience at the same dose.
What are the side effects of Adderall and Vyvanse?
Both share common stimulant class side effects: decreased appetite (most common — especially at lunchtime), insomnia if taken too late in the day, increased heart rate and blood pressure, headache, dry mouth, and irritability — particularly as the medication wears off. Vyvanse's smoother prodrug conversion generally produces milder peaks and troughs, with less pronounced appetite suppression and rebound than Adderall IR. Both are DEA Schedule II controlled substances with potential for misuse and psychological dependence at non-therapeutic doses; at prescribed therapeutic doses, risk of addiction in patients with genuine ADHD is low.
Is Vyvanse available as a generic in 2026?
Yes — the FDA approved generic versions of Vyvanse (lisdexamfetamine dimesylate) in August 2023, with 14 manufacturers now approved to produce it. Generic lisdexamfetamine is available in the same strengths as brand-name Vyvanse. Supply has improved since initial generic approval though some regional and formulation-specific shortages persist in 2026. Generic lisdexamfetamine is significantly less expensive than brand-name Vyvanse — making ADHD treatment more accessible for patients without comprehensive prescription drug coverage.
What non-stimulant options exist for ADHD?
For patients who cannot tolerate stimulants or have contraindications, evidence-based non-stimulant options include: atomoxetine (Strattera) — a norepinephrine reuptake inhibitor, not controlled, takes 2 to 6 weeks for full effect; viloxazine (Qelbree) — FDA-approved in 2021 for children and 2023 for adults; guanfacine (Intuniv) and clonidine (Kapvay) — alpha-2 agonists particularly useful for hyperactivity and emotional dysregulation; and bupropion off-label for adult ADHD with comorbid depression. Non-stimulants do not produce the immediate effect of stimulants and require weeks to reach full efficacy, but are appropriate for patients with significant anxiety, cardiovascular contraindications, or concerns about stimulant abuse potential.
Comments